A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson’s disease, according to results from a phase 1 clinical ...

Other companies working in the category NLRP3, meanwhile, include Bristol-Myers Squibb, Roche, Novartis, Zydus, and Cerevance. Swisher said that NodThera is leading the NLRP3 inflammasome space ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

Researchers recently screened 6,000 approved or development stage compounds and found eight drugs that activate CHK2 — a protein that helps repair DNA damage but is reduced in the cells of kids ...